Business
Conditional Placing to Raise £3 Million
Conditional Placing to Raise £3 Million.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0448T\n Roquefort Investments PLC\n 22 November 2021\n \n \n \n \n NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM) OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. \n \n \n \n \n \n FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN ANY JURISDICTION.\n \n \n \n \n \n 22 November 2021\n \n \n \n \n \n \n \n \n Roquefort Investments plc\n \n \n (\"Roquefort Investments\" or the \"Company\")\n \n \n \n \n \n Conditional Placing to Raise £3 Million (Before Expenses)\n \n \n \n \n \n Roquefort Investments (LSE:ROQ), the London listed \n investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector\n , is pleased to announce that it has conditionally raised £3 million (before expenses) (the \"Placing\") via the proposed issue of 30,000,000 new Ordinary Shares (the \"Placing Shares\") at a price of 10 pence per new Ordinary Share (the \"Placing Price\").\n \n \n \n \n \n As announced on 18 November 2021 the Company has entered into a conditional share sale and purchase agreement (the \"Acquisition Agreement\") with Provelmare Holding S.A. pursuant to which Roquefort Investments has agreed to acquire the entire issued share capital of Lyramid Pty Limited for an initial consideration of £1 million payable 50% in cash and 50% in shares (the \"Acquisition\"). The Acquisition is conditional, inter alia, on a successful Placing.\n \n \n \n \n \n The net proceeds of the Placing are estimated at £2,560,000. The net proceeds, together with existing cash, are intended to be used to fund the cash component of the consideration for the Acquisition, pre-clinical drug development and working capital.\n \n \n \n \n \n On 19 November 2021 the Company circulated a notice of general meeting to shareholders to seek shareholder approval inter alia for the issue of new Ordinary Shares in connec...